Document is current

Article History

Received: 13 August 2020

Accepted: 4 February 2021

First Online: 11 February 2021

Declarations

:

: This study was approved by the Duke University Institutional Review Board.

: Being a secondary analysis of a retrospective chart review study, there were no study participants, just data. As such, no consent was obtained nor required by the IRB.

: N/A

: Jesse D. Troy: Consulting services to the Community Data Roundtable, AegisCN, Gamida Cell, The EMMES Corporation, Sino Cell Technologies, Cohortias, International, and Synthetic Biologics unrelated to this work.Thomas W. LeBlanc: Personal fees for consulting or advisory boards from AbbVie, Agios, AstraZeneca, Amgen, Carevive, BMS/Celgene, Daiichi-Sankyo, Heron, Otsuka, Pfizer, and Seattle Genetics; royalties from UpToDate; speakers bureau fees from Agios, AbbVie, and BMS/Celgene; grants and/or research contracts from the American Cancer Society, AstraZeneca, BMS, Jazz Pharmaceuticals, the NINR/NIH, and Seattle Genetics.

: All analyses were done using SAS v9.4 (SAS Institute, Cary, NC). Code can be made available from the statistician upon request.